Source-grounded facts extracted from MYRIAD GENETICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MYRIAD GENETICS INC shareholders approved Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan at the 2026-06-04 meeting.
“Proposal No. 5: Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan Votes Votes Votes Broker For Against Abstained Non-Votes 59,389,193 3,066,087 48,040 15,255,311 The stockholders voted to approve the 2026 Plan.”
MYRIAD GENETICS INC shareholders approved Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan at the 2026-06-04 meeting.
“Proposal No. 4: Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan Votes Votes Votes Broker For Against Abstained Non-Votes 61,812,338 650,741 40,241 15,255,311 The stockholders voted to approve the proposed amendment to the Purchase Plan to increase the aggregate number of shares of common stock available for issuance under the Purchase Plan by an additional 4,000,000 shares.”
MYRIAD GENETICS INC shareholders approved Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement at the 2026-06-04 meeting.
“Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 59,356,710 3,098,966 47,644 15,255,311 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”
MYRIAD GENETICS INC shareholders approved Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 Votes Votes Votes For Against Abstained 76,302,595 1,391,172 64,864 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was approved by stockholders.”
MYRIAD GENETICS INC shareholders approved Election of Directors at the 2026-06-04 meeting.
“Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes Paul M. Bisaro 61,842,900 637,156 23,264 15,255,311 Rashmi Kumar 60,399,633 2,071,375 32,312 15,255,311 Lee N. Newcomer, M.D 61,576,936 894,837 31,547 15,255,311 Each of Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D. was elected to serve as a Class III director of the Company for a term expiring at the 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.”
MYRIAD GENETICS INC reported first quarter ended March 31, 2026 results: revenue 200.4 million, net income net loss of $34.1 million, EPS loss per share was $0.09 per share. Guidance reaffirmed.
“First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.”
MYRIAD GENETICS INC incurred credit facility of $200 million term loan credit facility with OrbiMed Royalty & Credit Opportunities IV, LP at the greater of the one-month SOFR Rate and 2.50% plus 6.50% maturing July 31, 2030.
“On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum principal amount of $125 million, which amount was funded on the Closing Date, and delayed draw term loans (the “Delayed Draw Loans” and together with the Initial Loan, the “Loans”) at the election of the Company on or prior to June 30, 2027, in a maximum principal amount of $75 million (the “Credit Facility”).”
Samraat S. Raha was appointed as Director at MYRIAD GENETICS INC.
“the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.”
Samraat S. Raha was appointed as President and Chief Executive Officer at MYRIAD GENETICS INC.
“the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.”
Paul J. Diaz departed as President and Chief Executive Officer at MYRIAD GENETICS INC.
“Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025”
MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.
“Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year”
MYRIAD GENETICS INC reported the three months ended December 31, 2023 results: revenue $197 million, EPS $(0.36). Guidance raised.
“Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance.”
MYRIAD GENETICS INC reported fourth quarter 2023 results: revenue between approximately $196 and $197 million, EPS diluted GAAP earnings per share of between ($0.35) an d ($0.36), adj usted earnings per share of between $0.02 and $0.03. Guidance reaffirmed.
“The Company also disclosed preliminary financial data for the fourth quarter of 2023, specifically that the Company expects fourth quarter 2023 revenue of between approximately $196 and $197 million, diluted GAAP earnings per share of between ($0.35) an d ($0.36), adj usted earnings per share of between $0.02 and $0.03, and GAAP and adjusted gross margin of approximately 70%.”
Scott J. Leffler was appointed as Chief Financial Officer at MYRIAD GENETICS INC.
“On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.”
R. Bryan Riggsbee departed as Chief Financial Officer at MYRIAD GENETICS INC.
“On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.”
MYRIAD GENETICS INC entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (effective 2023-11-08).
“On November 8, 2023, Myriad Genetics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (the “Underwriters”), relating to the issuance and sale pursuant to an underwritten public offering (the “Offering”) of an aggregate of 6,470,588 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and up to 970,588 additional shares of Common Stock at the Underwriters’ option.”
MYRIAD GENETICS INC reported three months ended September 30, 2023 results: revenue $191.9 million, EPS $(0.75). Guidance raised.
“respectively. ▪ Prenatal test volumes grew 20% and 14% year-over-year, respectively, excluding contributions from the SneakPeek Early Gender DNA Test. • Third quarter revenue of $191.9 million, grew 23% year-over-year, inclusive of a $7.1 million change of estimate 1 in the current quarter versus $(5.3) million change of estimate 1 in the third quarter of 2022.”
Samraat S. Raha was appointed as Chief Operating Officer at MYRIAD GENETICS INC.
“On October 16, 2023, the Board of Directors (the "Board") of Myriad Genetics, Inc. (the "Company" or "Myriad") appointed Samraat S. Raha ("Mr. Raha") as the Company's Chief Operating Officer, effective as of December 11, 2023.”
Nicole Lambert departed as Chief Operating Officer at MYRIAD GENETICS INC.
“On October 4, 2023, Nicole Lambert, Chief Operating Officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Ms. Lambert would step down from such position, effective October 31, 2023”
MYRIAD GENETICS INC reported second quarter ended June 30, 2023 results: revenue $183.5 million, EPS $(1.42). Guidance reaffirmed.
“volumes grew 23% year-over-year. ▪ Prenatal test volumes grew 12% year-over-year, excluding contributions from the SneakPeek Early Gender DNA Test. • Second quarter revenue of $183.5 million, grew 2% year-over-year, inclusive of a $11.7 million change of estimate in the second quarter of 2022 versus an immaterial amount in the current quarter. Excluding these change”
MYRIAD GENETICS INC incurred revolving credit of $90,000,000 with JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank at ABR plus an applicable margin ranging from 1.00% to 1.50% or Adjusted Term SOFR maturing June 30, 2026.
“On June 30, 2023 (the "Closing Date"), Myriad Genetics, Inc. (the "Company") entered into a Credit Agreement (the "Credit Agreement") with the lenders from time to time party thereto ("Lenders"), certain of the Company's domestic subsidiaries party thereto (the "Guarantors"), and JP Morgan Chase Bank, N.A., as Administrative Agent (in such capacity, "Administrative Agent") and as Issuing Bank, consisting of a revolving credit facility in an initial maximum principal amount of $90,000,000, with an option to increase the maximum principal amount by up to $25,000,000 (the "Credit Facility").”
MYRIAD GENETICS INC entered into Credit Agreement with JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank, and the lenders from time to time party thereto valued at $90,000,000 (effective 2023-06-30).
“On June 30, 2023 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), certain of the Company’s domestic subsidiaries party thereto (the “Guarantors”), and JP Morgan Chase Bank, N.A., as Administrative Agent (in such capacity, “Administrative Agent”) and as Issuing Bank, consisting of a revolving credit facility in an initial maximum principal amount of $90,000,000, with an option to increase the maximum principal amount by up to $25,000,000 (the “Credit Facility”).”
MYRIAD GENETICS INC: Stockholders approved an amendment to the Restated Certificate of Incorporation to add a federal forum selection clause for claims under the Securities Act of 1933 (effective 2023-06-01).
“The Company's stockholders also voted at the Annual Meeting to approve an amendment to the Restated Certificate of Incorporation to add a federal forum selection clause for claims under the Securities Act of 1933, as amended (the "Federal Forum Selection Clause Amendment" and together with the Officer Exculpation Amendment, the "Amendments").”
MYRIAD GENETICS INC: Stockholders approved an amendment to the Restated Certificate of Incorporation to limit personal liability of certain senior officers (Officer Exculpation Amendment) (effective 2023-06-01).
“On June 1, 2023, the Company's stockholders voted at the Annual Meeting to approve an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Restated Certificate of Incorporation") to limit the personal liability of certain senior officers of the Company as permitted by recent amendments to Delaware law (the "Officer Exculpation Amendment").”
MYRIAD GENETICS INC shareholders approved To Approve an Amendment to the Company's Restated Certificate of Incorporation to Limit Personal Liability of Certain Senior Officers of the Company at the 2023-06-01 meeting.
“Proposal No. 7: To Approve an Amendment to the Company's Restated Certificate of Incorporation to Limit Personal Liability of Certain Senior Officers of the Company Votes Votes Votes Broker For Against Abstained Non-Votes 59,118,369 11,652,693 119,219 3,608,837 The stockholders voted to approve the Officer Exculpation Amendment.”
MYRIAD GENETICS INC shareholders approved To Approve an Amendment to the Company's Restated Certificate of Incorporation to Add a Federal Forum Selection Clause at the 2023-06-01 meeting.
“Proposal No. 6: To Approve an Amendment to the Company's Restated Certificate of Incorporation to Add a Federal Forum Selection Clause Votes Votes Votes Broker For Against Abstained Non-Votes 64,586,633 6,222,162 81,486 3,608,837 The stockholders voted to approve the Federal Forum Selection Clause Amendment.”
MYRIAD GENETICS INC shareholders approved Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants at the 2023-06-01 meeting.
“Proposal No. 5: Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants Votes Votes Votes Broker For Against Abstained Non-Votes 66,996,613 3,829,841 63,827 3,608,837 The stockholders voted to approve the proposed amendment to the 2017 Plan to increase the aggregate number of shares of common stock available for the grant of awards under the 2017 Plan by an additional 4.8 million shares.”
MYRIAD GENETICS INC shareholders approved Advisory Vote on the Frequency of Holding an Advisory Vote on the Compensation of Our Named Executive Officers at the 2023-06-01 meeting.
“Proposal No. 4: Advisory Vote on the Frequency of Holding an Advisory Vote on the Compensation of Our Named Executive Officers Votes Votes Votes Votes Every One Year Every Two Years Every Three Years Abstained 67,953,555 8,982 2,912,353 15,391 The stockholders voted to approve, on an advisory basis, one year as the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.”
MYRIAD GENETICS INC shareholders approved Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement at the 2023-06-01 meeting.
“Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 68,121,537 2,731,973 36,771 3,608,837 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”
MYRIAD GENETICS INC shareholders approved Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-06-01 meeting.
“Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 Votes Votes Votes For Against Abstained 71,921,900 2,563,981 13,237 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved by stockholders.”
MYRIAD GENETICS INC shareholders approved Election of Directors at the 2023-06-01 meeting.
“Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes Paul M. Bisaro 70,549,855 311,078 29,348 3,608,837 Rashmi Kumar 69,479,076 1,382,472 28,733 3,608,837 Lee N. Newcomer, M.D. 70,034,002 839,343 16,936 3,608,837 Each of Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D., was elected to serve as a director of the Company for a term expiring at the 2026 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.”
MYRIAD GENETICS INC reported the three months ended March 31, 2023 results: EPS $(0.67). Guidance raised.
“Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range”
MYRIAD GENETICS INC reported fourth quarter ended December 31, 2022 results: revenue $177.8 million, EPS $(0.52). Guidance initiated.
“Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year”
MYRIAD GENETICS INC reported the three months ended September 30, 2022 results: revenue $156.4 million, EPS $(0.43).
“Myriad Genetics Reports Third Quarter Financial Results Highlights: • Revenue of $156.4 million for the quarter ended September 30, 2022. ▪ Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates 1 ($5.3 million). ▪ Third quarter testing volumes, excluding divested businesses, grew 12% year-over-year. Hereditary cancer testing volume continued to improve in 2022 and grew 4% year-over-year in the third quarter. GeneSight volumes grew 34% over third quarter of 2021. ▪ We believe that the underlying pricing of Myriad testing products remains stable, notwithstanding that average selling price overall was negatively impacted by currency translations, change of estimates and a non-recurring milestone payment in the third quarter. • Diluted GAAP earnings per share (EPS) were $(0.43) and adjusted EPS were $(0.19) in the third quarter of 2022 .”
Dennis Langer resigned as Director at MYRIAD GENETICS INC.
“On June 28, 2022, Dennis Langer, a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”), notified the Company that he is resigning as a director, effective June 30, 2022.”
Natalie Munk changed role as Chief Accounting Officer and Principal Accounting Officer at MYRIAD GENETICS INC.
“On June 2, 2022, the Board of Directors of Myriad Genetics, Inc. (the "Company") designated Natalie Munk, the Company's Chief Accounting Officer, to serve as the Company's principal accounting officer.”
Jerry Lanchbury retired as Chief Scientific Officer at MYRIAD GENETICS INC.
“As previously disclosed, Dr. Lanchbury announced his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.”
Jerry Lanchbury retired as Chief Scientific Officer at MYRIAD GENETICS INC.
“On January 3, 2022, Jerry Lanchbury, Ph.D., notified Myriad Genetics, Inc. (the "Company") of his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.”
Nicole Lambert was appointed as Chief Operating Officer at MYRIAD GENETICS INC.
“On December 14, 2021, Myriad Genetics, Inc. (the “Company”) announced that Nicole Lambert, currently serving as its Group President, Myriad Women's Health, Oncology and International, has been appointed Chief Operating Officer of the Company, effective January 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.